Parkinson's disease (PD) affects many people over 60 and can cause serious problems in daily life. While some medicines help early on, they can lead to issues later. One treatment for PD is deep brain stimulation (DBS), which involves placing electrodes in the brain to send electrical signals and help manage symptoms. Conventional DBS (cDBS) uses constant settings, which may not always work well as symptoms change throughout the day.

To improve this, adaptive DBS (aDBS) adjusts the settings automatically based on the patient's needs. aDBS was approved by the U.S. Food and Drug Administration (FDA) for use with the Percept device. This study aims to test a new method to set aDBS parameters using data-driven techniques to make it easier for more people to use.

• The study involves multiple sessions over a period of time.
• Participants will switch between aDBS and cDBS to compare their effectiveness.
• Possible risks include temporary worsening of symptoms or skin irritation.

Participants must be 25-75 years old, have PD, and already use a Percept DBS device. They should not have significant depression or other disorders that could affect the study.